학술논문
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial
Document Type
Article
Author
Zhao, Fang-Hui ; Wu, Ting ; Hu, Yue-Mei ; Wei, Li-Hui ; Li, Ming-Qiang ; Huang, Wei-Jin ; Chen, Wen ; Huang, Shou-Jie ; Pan, Qin-Jing; Zhang, Xun; Hong, Ying; Zhao, Chao; Li, Qing; Chu, Kai; Jiang, Yun-Fei; Li, Ming-Zhu; Tang, Jie; Li, Cai-Hong; Guo, Dong-Ping; Ke, Li-Dong; Wu, Xin; Yao, Xing-Mei; Nie, Jian-Hui; Lin, Bi-Zhen; Zhao, Yu-Qian; Guo, Meng; Zhao, Jun; Zheng, Feng-Zhu; Xu, Xiao-Qian; Su, Ying-Ying; Zhang, Qiu-Fen; Sun, Guang; Zhu, Feng-Cai; Li, Shao-Wei; Li, Yi-Min; Pan, Hui-Rong; Zhang, Jun ; Qiao, You-Lin; Xia, Ning-Shao
Source
In The Lancet Infectious Diseases December 2022 22(12):1756-1768
Subject
Language
ISSN
1473-3099